AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus.

Company profile
Ticker
AIM
Exchange
Website
CEO
Thomas Equels
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Exelixis • Sana Biotechnology • Ginkgo Bioworks • Bio-Techne ...
Former names
HEMISPHERX BIOPHARMA INC
SEC CIK
Corporate docs
Subsidiaries
BioPro Corp. • BioAegean Corp. • Hemispherx Biopharma Europe ...
IRS number
520845822
AIM stock data
News

Why IZEA Worldwide Shares Are Trading Higher By Over 30%: Here Are 37 Stocks Moving Premarket
16 Aug 22
Recap: AIM ImmunoTech Q2 Earnings
15 Aug 22
AIM ImmunoTech Q2 EPS $(0.10) Up From $(0.12) YoY
15 Aug 22
Earnings Scheduled For August 12, 2022
12 Aug 22
Why Celyad Oncology Is Trading Higher By Over 31%; Here Are 29 Stocks Moving Premarket
1 Aug 22
Press releases
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation
15 Aug 22
AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update
15 Aug 22
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID
28 Jul 22
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data
20 Jul 22
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series
14 Jul 22
Investment data
Securities sold
Number of investors
Calendar
15 Aug 22
16 Aug 22
31 Dec 22
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 34.45M | 34.45M | 34.45M | 34.45M | 34.45M | 34.45M |
Cash burn (monthly) | (no burn) | 557.5K | 1.57M | 1.6M | 771K | 1.19M |
Cash used (since last report) | n/a | 875.91K | 2.46M | 2.52M | 1.21M | 1.87M |
Cash remaining | n/a | 33.58M | 31.99M | 31.94M | 33.24M | 32.58M |
Runway (months of cash) | n/a | 60.2 | 20.4 | 19.9 | 43.1 | 27.4 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
18 Jul 22 | Equels Thomas K. | Common Stock | Grant | Acquire A | No | No | 0.76 | 32,895 | 25K | 382,704 |
25 Apr 22 | Equels Thomas K. | Common Stock | Grant | Acquire A | No | No | 1.02 | 49,020 | 50K | 349,809 |
25 Apr 22 | Iii Peter W. Rodino | Common Stock | Grant | Acquire A | No | No | 1.02 | 4,902 | 5K | 63,193 |
25 Apr 22 | Stewart Appelrouth | Common Stock | Grant | Acquire A | No | No | 1.07 | 24,500 | 26.22K | 136,417 |
Institutional ownership, Q1 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0 |
Total shares | 0 |
Total puts | 0 |
Total calls | 0 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|
Financial report summary
?Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
Absent, acquire, activist, analyzing, attempt, attention, Bioscience, blind, campaign, Chancellor, Chancery, Chioini, composition, concert, connection, contest, context, costly, Court, declaratory, defective, Delaware, Deutsch, difficult, disregarded, District, divert, diverted, effectuate, enjoin, exploited, Franz, hearing, injunctive, instability, invalid, Jonathan, Jorgl, judgement, Kellner, Lautz, lawsuit, litigation, Merck, Michael, Middle, Monday, motion, Nederland, NJBC, nominate, nomination, noncompliance, notice, Octrooicentrum, ORR, Overview, perception, personnel, prevail, purported, purporting, pursuit, qualified, regular, relief, restraining, retain, Rice, satisfy, set, smallpox, speculative, stipulation, stockholder, sued, takeover, Ted, temporary, thereunder, Todd, TRO, Tudor, unanimously, unlawful, Vaccinia, Vice, Walter
Financial reports
Current reports
8-K
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid
18 Jul 22
8-K
AIM ImmunoTech Secures New State-of-the-Art Facility for Product Development and Testing
21 Jun 22
8-K
Entry into a Material Definitive Agreement
17 Jun 22
8-K
Clinical Development Program for the Treatment of Pancreatic Cancer
12 Apr 22
8-K
Regulation FD Disclosure
28 Mar 22
8-K
Other Events
16 Mar 22
8-K
AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey
7 Mar 22
8-K
AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer
3 Mar 22
8-K
Regulation FD Disclosure
27 Jan 22
8-K
Regulation FD Disclosure
26 Jan 22
Registration and prospectus
S-8
Registration of securities for employees
1 Jul 22
S-3
Shelf registration
21 Jan 22
POS AM
Prospectus update (post-effective amendment)
18 Jan 22
S-8
Registration of securities for employees
1 Jul 21
424B5
Prospectus supplement for primary offering
18 Aug 20
S-8
Registration of securities for employees
3 Aug 20
424B5
Prospectus supplement for primary offering
15 Jun 20
424B5
Prospectus supplement for primary offering
10 Mar 20
424B5
Prospectus supplement for primary offering
3 Mar 20
424B4
Prospectus supplement with pricing info
26 Sep 19
Other
EFFECT
Notice of effectiveness
7 Feb 22
CORRESP
Correspondence with SEC
30 Jan 22
UPLOAD
Letter from SEC
25 Jan 22
EFFECT
Notice of effectiveness
24 Jan 22
EFFECT
Notice of effectiveness
26 Sep 19
UPLOAD
Letter from SEC
25 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
CORRESP
Correspondence with SEC
23 Sep 19
UPLOAD
Letter from SEC
23 Sep 19
Ownership
4
AIM ImmunoTech / Thomas K Equels ownership change
18 Jul 22
4
AIM ImmunoTech / STEWART APPELROUTH ownership change
27 Apr 22
4
AIM ImmunoTech / Peter W Rodino III ownership change
26 Apr 22
4
AIM ImmunoTech / Thomas K Equels ownership change
26 Apr 22
3
AIM ImmunoTech / Robert IV Dickey ownership change
4 Apr 22
4
AIM ImmunoTech / Peter W Rodino III ownership change
4 Mar 22
4
AIM ImmunoTech / WILLIAM M MITCHELL ownership change
4 Mar 22
4
AIM ImmunoTech / ELLEN M LINTAL ownership change
4 Mar 22
4
AIM ImmunoTech / Thomas K Equels ownership change
4 Mar 22
4
AIM ImmunoTech / STEWART APPELROUTH ownership change
4 Mar 22
Patents
Utility
Compositions and Methods for Cancer Therapy
31 Mar 22
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound in any order together or separately.
Utility
Methods for Improving Exercise Tolerance In Myalgic Encephalomyelitis Patients
3 Mar 22
The present invention relates to methods for treating a subject with myalgic encephalomyelitis/chronic fatigue syndrome symptoms comprising administering a target subject a pharmaceutical composition comprising a therapeutic dsRNA (tdsRNA).
Utility
Compositions for Cancer Therapy and Methods
1 Jul 21
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately.
Utility
Compositions for Cancer Therapy and Methods
24 Jun 20
One aspect of this disclosure is directed to a method for treating a cancer in a subject in need thereof by administering to the subject at least a first compound and a second compound together or separately.
Reddit threads
Daily Discussion Thread - August 16th, 2022
16 Aug 22
Daily Discussion Thread - August 15th, 2022
15 Aug 22
Hudson Technologies - HDSN - Moat, Increasing Demand, Diminishing Supply - DD
6 Aug 22
Can stocks really ever go to ZERO?
29 Jul 22
💰💰💰Good morning! #premarket #watchlist 07/20 $GNLN -Greenlane Completes Sale of Interest in VIBES , $SLNO -Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome, $AIM -additional patient data from Single-Center Named Patient Program evaluating Ampligen
20 Jul 22
💰💰💰Good morning! #premarket #watchlist 07/20 $GNLN -Greenlane Completes Sale of Interest in VIBES , $SLNO -Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome, $AIM -additional patient data from Single-Center Named Patient Program evaluating Ampligen
20 Jul 22
💰💰💰Good morning! #premarket #watchlist 07/20 $GNLN -Greenlane Completes Sale of Interest in VIBES , $SLNO -Provides Regulatory Update on DCCR for the Treatment of Prader-Willi Syndrome, $AIM -additional patient data from Single-Center Named Patient Program evaluating Ampligen
20 Jul 22
bearish on $TSLA
7 Jul 22
What are your top picks for bankruptcy in the next 18 months?
2 Jul 22
What Are Your Moves Tomorrow - June 16, 2022
15 Jun 22